» Articles » PMID: 20484041

The Fbw7 Tumor Suppressor Targets KLF5 for Ubiquitin-mediated Degradation and Suppresses Breast Cell Proliferation

Overview
Journal Cancer Res
Specialty Oncology
Date 2010 May 21
PMID 20484041
Citations 90
Authors
Affiliations
Soon will be listed here.
Abstract

Fbw7 is a tumor suppressor frequently inactivated in cancers. The KLF5 transcription factor promotes breast cell proliferation and tumorigenesis through upregulating FGF-BP. The KLF5 protein degrades rapidly through the ubiquitin proteasome pathway. Here, we show that the Skp1-CUL1-Fbw7 E3 ubiquitin ligase complex (SCF(Fbw7)) targets KLF5 for ubiquitin-mediated degradation in a GSK3beta-mediated KLF5 phosphorylation-dependent manner. Mutation of the critical S303 residue in the KLF5 Cdc4 phospho-degrons motif ((303)SPPSS) abolishes the protein interaction, ubiquitination, and degradation by Fbw7. Inactivation of endogenous Fbw7 remarkably increases the endogenous KLF5 protein abundances. Endogenous Fbw7 suppresses the FGF-BP gene expression and breast cell proliferation through targeting KLF5 for degradation. These findings suggest that Fbw7 inhibits breast cell proliferation at least partially through targeting KLF5 for proteolysis. This new regulatory mechanism of KLF5 degradation may result in useful diagnostic and therapeutic targets for breast cancer and other cancers.

Citing Articles

Gallium complex K6 inhibits colorectal cancer by increasing ROS levels to induce DNA damage and enhance phosphatase and tensin homolog activity.

Li W, Yang C, Cheng Z, Wu Y, Zhou S, Qi X MedComm (2020). 2024; 5(8):e665.

PMID: 39049965 PMC: 11266899. DOI: 10.1002/mco2.665.


KLF5 inhibition initiates epithelial-mesenchymal transition in non-transformed human squamous epithelial cells.

Bhargava D, Rusakow D, Zheng W, Awad S, Katz J Biochim Biophys Acta Mol Cell Res. 2024; 1871(7):119789.

PMID: 38909912 PMC: 11365763. DOI: 10.1016/j.bbamcr.2024.119789.


Accumulation of TOX high mobility group box family member 3 promotes the oncogenesis and development of hepatocellular carcinoma through the MAPK signaling pathway.

Peng Y, Yu J, Liu F, Tang L, Li B, Zhang W MedComm (2020). 2024; 5(3):e510.

PMID: 38463397 PMC: 10924639. DOI: 10.1002/mco2.510.


FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies.

Wang W, Jiang K, Liu X, Li J, Zhou W, Wang C Front Pharmacol. 2023; 14:1278056.

PMID: 38027013 PMC: 10680170. DOI: 10.3389/fphar.2023.1278056.


Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy.

Jiang Y, Ni S, Xiao B, Jia L Acta Pharm Sin B. 2023; 13(11):4341-4372.

PMID: 37969742 PMC: 10638515. DOI: 10.1016/j.apsb.2023.07.019.